• Avedro, Inc.
    Cataract/Anterior Segment, Cornea/External Disease, Refractive Mgmt/Intervention

    Avedro, Inc., has received European CE Mark clearance to market its KXL II cross-linking system, which uses PiXL (Photorefractive Intrastromal Cross-linking).

    The company says the KXL II system has the potential to nonsurgically correct myopia and to improve cataract surgery outcomes.

    “The KXL II and PiXL procedure continue our mission to make refractive correction truly nonsurgical,” said David Muller, PhD, CEO of Avedro. “Treating myopia and other refractive disorders with PiXL has the potential to open up refractive correction to millions of people who have never considered LASIK surgery before but would consider a nonsurgical alternative.”

    A. John Kanellopoulos, MD, clinical professor of ophthalmology at NYU School of Medicine and a member of Avedro’s Medical Advisory Board, adds: “As one of the first KXL II clinical sites, we experienced the amazing capabilities of customized accelerated cross-linking to achieve specific, reproducible and interim-stable refractive changes on the cornea. It seems to me that every surgeon who has performed cross-linking has experienced refractive corneal changes. We now have a way to design and customize these refractive changes.”